Trial Profile
A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 May 2021 According to an Rafael Pharmaceuticals media release, data from this trial will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021.
- 20 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jun 2018 Planned number of patients changed from 45 to 33.